Janus Henderson Group Portfolio holdings
Janus Henderson Group, formed in 2017 through the merger of Janus Capital Group (founded 1969) and Henderson Group (founded 1934), is a global asset management firm headquartered in London, managing over $350 billion in assets as of late 2024 for institutional, retail, and high-net-worth clients. With a strong presence in the U.S., Europe, and Asia-Pacific, the firm offers a wide range of investment products, including equities, fixed income, multi-asset, and alternative strategies, often blending active management with research-driven insights. Known for its equity expertise from Janus’s growth-focused heritage and Henderson’s European fixed-income strengths, Janus Henderson serves clients through mutual funds, ETFs, and bespoke portfolios, emphasizing risk-adjusted returns and ESG integration. Led by CEO Ali Dibadj since 2022, the publicly traded firm (NYSE: JHG) continues to refine its strategy amid competitive pressures, maintaining a foothold in key markets worldwide.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Rentokil
RTO
|
+$514M |
| 2 |
APLS
Apellis Pharmaceuticals
APLS
|
+$210M |
| 3 |
TFI International
TFII
|
+$145M |
| 4 |
Ambev
ABEV
|
+$142M |
| 5 |
Vanguard S&P 500 ETF
VOO
|
+$133M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$8.38B |
| 2 |
Apple
AAPL
|
+$5.7B |
| 3 |
Amazon
AMZN
|
+$3.72B |
| 4 |
Alphabet (Google) Class C
GOOG
|
+$3.64B |
| 5 |
Mastercard
MA
|
+$3.47B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 28.11% |
| 2 | Healthcare | 21.42% |
| 3 | Financials | 11.42% |
| 4 | Industrials | 10.73% |
| 5 | Consumer Discretionary | 10.04% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
626
Charles River Laboratories
CRL
$11.3B
| $15M | 0.01% |
68,679
+64,508
| +1,547% | +$14.1M |
|
627
Gibraltar Industries
ROCK
$1.27B
| $14.7M | 0.01% |
321,202
-322,880
| -50% | -$15.5M |
|
628
MetLife
MET
$62.5B
| $14.7M | 0.01% |
203,413
-79,807
| -28% | -$5.72M |
|
629
Lockheed Martin
LMT
$132B
| $14.6M | 0.01% |
30,078
-1,624
| -5% | -$755K |
|
630
Phreesia
PHR
$656M
| $14.6M | 0.01% |
450,415
-370,759
| -45% | -$10.1M |
|
631
IBM
IBM
$209B
| $14.4M | 0.01% |
102,451
-92,299
| -47% | -$12.7M |
|
632
LoveSac
LOVE
$236M
| $14.4M | 0.01% |
653,642
-653,830
| -50% | -$14.6M |
|
|
FNA
633
DELISTED
Paragon 28, Inc.
FNA
| $14.3M | 0.01% |
749,949
-749,949
| -50% | -$14.2M |
|
|
KVSC
634
DELISTED
Khosla Ventures Acquisition Co. III Class A Common Stock
KVSC
| $14.2M | 0.01% |
1,430,361
-740,361
| -34% | -$7.34M |
|
635
John Wiley & Sons Class A
WLY
$2.66B
| $14.2M | 0.01% |
355,173
-514,039
| -59% | -$21.5M |
|
|
HES
636
DELISTED
Hess
HES
| $14.1M | 0.01% |
99,655
-216,325
| -68% | -$29.7M |
|
637
Kornit Digital
KRNT
$695M
| $14.1M | 0.01% |
614,724
-302,070
| -33% | -$7.55M |
|
638
Medpace
MEDP
$16.1B
| $14.1M | 0.01% |
66,340
-69,056
| -51% | -$13.8M |
|
639
Halliburton
HAL
$26.4B
| $14.1M | 0.01% |
358,121
+138,629
| +63% | +$4.91M |
|
|
VRNA
640
DELISTED
Verona Pharma
VRNA
| $14.1M | 0.01% |
538,634
-61,366
| -10% | -$817K |
|
|
WBX
641
Wallbox
WBX
$77.4M
| $14M | 0.01% |
195,840
-185,830
| -49% | -$21.1M |
|
642
Landstar System
LSTR
$5.75B
| $14M | 0.01% |
85,826
+62,386
| +266% | +$10M |
|
|
VIVO
643
DELISTED
Meridian Bioscience Inc
VIVO
| $13.9M | 0.01% |
418,615
-219,187
| -34% | -$7.06M |
|
|
STOR
644
DELISTED
STORE Capital Corporation
STOR
| $13.8M | 0.01% |
429,260
-210,484
| -33% | -$6.68M |
|
645
AT&T
T
$159B
| $13.8M | 0.01% |
747,179
-723,419
| -49% | -$12.9M |
|
646
Yeti Holdings
YETI
$3.76B
| $13.6M | 0.01% |
330,060
-433,498
| -57% | -$16.3M |
|
647
Vanguard High Dividend Yield ETF
VYM
$80.9B
| $13.5M | 0.01% |
124,738
+602
| +0.5% | +$64.1K |
|
648
Boeing
BA
$175B
| $13.4M | 0.01% |
70,557
-68,345
| -49% | -$11.2M |
|
|
PENG
649
Penguin Solutions Inc
PENG
$2.64B
| $13.4M | 0.01% |
898,559
-2,014,839
| -69% | -$30.8M |
|
|
KVSA
650
DELISTED
Khosla Ventures Acquisition Co. Class A Common Stock
KVSA
| $13.3M | 0.01% |
1,332,534
-20,522
| -2% | -$204K |
|
Similar funds
Janus Henderson Group's Q4 2022 Portfolio in Review
As of Q4 2022, Janus Henderson Group held 2,666 positions worth $140B, down 48% from $267B the previous quarter. Its ten largest holdings account for 22% of the portfolio.
Janus Henderson Group withdrew a net $148B in Q4 2022, closing 210 positions and reducing 1,907 holdings. Its most notable exit was Terminix Global Holdings, Inc., an estimated $901M position sold in full.
By sector, the portfolio is most concentrated in Technology at 28% of assets, down from 30% a quarter earlier, followed by Healthcare and Financials.
Against the trend, Janus Henderson Group opened a new position in Rentokil worth $510M.
- Janus Henderson Group's largest Q4 2022 buy was Rentokil: 16,564,405 shares worth $510M.
- Janus Henderson Group added most to Apellis Pharmaceuticals in Q4 2022, an estimated $210M increase.
- Janus Henderson Group's biggest Q4 2022 reduction was Microsoft, cutting an estimated $8.38B.
- Janus Henderson Group fully exited Terminix Global Holdings, Inc. in Q4 2022, selling an estimated $901M.
- Janus Henderson Group's ten largest holdings make up 22% of its $140B portfolio in Q4 2022.
- Janus Henderson Group opened 131 new positions and closed 210 in Q4 2022.
- Janus Henderson Group's portfolio value fell 48% quarter-over-quarter to $140B.
Based on Janus Henderson Group's 13F filing for Q4 2022, filed 14 Feb 2023.